Salmonella Typhimurium TTSS-2 deficient mig-14 mutant shows attenuation in immunocompromised mice and offers protection against wild-type Salmonella Typhimurium infection

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Pati, Niladri Bhusan ^a   Vishwakarma, Vikalp ^a   Selvaraj, Sathish Kumar ^b   Dash, Sabyasachi ^a   Saha, Bhaskar ^b   Singh, Neera ^a   Suar, Mrutyunjay ^a  

^a KIIT UNIVERSITY   (India)

^b NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CD40 LIGAND; INTERLEUKIN 10; KANAMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL GROWTH; HISTOPATHOLOGY; IMMUNOGENICITY; MACROPHAGE; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; WILD TYPE;

MUS; SALMONELLA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; SALMONELLA TYPHIMURIUM;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL SECRETION SYSTEMS; DISEASE MODELS, ANIMAL; GENE DELETION; IMMUNITY, MUCOSAL; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA TYPHIMURIUM; SALMONELLA VACCINES; VACCINES, ATTENUATED;

EID: 84886900590     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-236     Document Type: Article

References (53)

1. Cell-mediated immune responses to a killed Salmonella enteritidis vaccine: lymphocyte proliferation, T-cell changes and interleukin-6 (IL-6), IL-1, IL-2, and IFN-gamma production. Okamura M, Lillehoj HS, Raybourne RB, Babu US, Heckert RA, Comp Immunol Microbiol Infect Dis 2004 27 4 255 272 10.1016/j.cimid.2003.12.001 15178000 (Pubitemid 38728923)
2. Analysis of immunization route-related variation in the immune response to heat-killed Salmonella typhimurium in mice. Thatte J, Rath S, Bal V, Infect Immun 1995 63 1 99 103 7806391
3. Humoral and cellular immune response generated by different vaccine programs before and after Salmonella Enteritidis challenge in chickens. Penha Filho RA, Moura BS, de Almeida AM, Montassier HJ, Barrow PA, Berchieri Junior A, Vaccine 2012 30 52 7637 7643 10.1016/j.vaccine.2012.10.020 23085366
4. Immune response of chicken gut to natural colonization by gut microflora and to Salmonella enterica serovar enteritidis infection. Crhanova M, Hradecka H, Faldynova M, Matulova M, Havlickova H, Sisak F, Rychlik I, Infect Immun 2011 79 7 2755 2763 10.1128/IAI.01375-10 21555397
5. Studies on the use of 9R strain of Salmonella gallinarum as a vaccine in chickens. Silva EN, Snoeyenbos GH, Weinack OM, Smyser CF, Avian Dis 1981 25 1 38 52 10.2307/1589825 7271663
6. Comparison of different attenuation strategies in development of a Salmonella hadar vaccine. Roland K, Tinge S, Warner E, Sizemore D, Avian Dis 2004 48 3 445 452 10.1637/7106 15529966 (Pubitemid 40234369)
7. Salmonella typhimurium infection in calves: protection and survival of virulent challenge bacteria after immunization with live or inactivated vaccines. Robertsson JA, Lindberg AA, Hoiseth S, Stocker BA, Infect Immun 1983 41 2 742 750 6347895 (Pubitemid 13074633)
8. Experimental model of oral antityphoid vaccination with live streptomycin-dependent Salmonella typhimurium in C57BL/6 mice. Vladoianu IR, Dubini F, J Hyg (Lond) 1975 75 2 215 218 10.1017/S0022172400047240 1100712
9. Sublethal infection of C57BL/6 mice with Salmonella enterica Serovar Typhimurium leads to an increase in levels of Toll-like receptor 1 (TLR1), TLR2, and TLR9 mRNA as well as a decrease in levels of TLR6 mRNA in infected organs. Totemeyer S, Kaiser P, Maskell DJ, Bryant CE, Infect Immun 2005 73 3 1873 1878 10.1128/IAI.73.3.1873-1878.2005 15731092 (Pubitemid 40470780)
10. Evaluation of Salmonella enterica serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice. Vishwakarma V, Pati NB, Chandel HS, Sahoo SS, Saha B, Suar M, PLoS One 2012 7 12 52043 10.1371/journal.pone.0052043 23284865
11. Immune response variations to Salmonella enterica serovar Typhi recombinant porin proteins in mice. Toobak H, Rasooli I, Talei D, Jahangiri A, Owlia P, Darvish Alipour Astaneh S, Biologicals 2013 41 4 224 230 10.1016/j.biologicals.2013.05.005 23796754
12. Comprehensive identification of Salmonella enterica serovar typhimurium genes required for infection of BALB/c mice. Chaudhuri RR, Peters SE, Pleasance SJ, Northen H, Willers C, Paterson GK, Cone DB, Allen AG, Owen PJ, Shalom G, et al. PLoS Pathog 2009 5 7 1000529 10.1371/journal.ppat.1000529 19649318
13. Rational design of Salmonella recombinant vaccines. Cheminay C, Hensel M, Int J Med Microbiol 2008 298 1-2 87 98 17888730 (Pubitemid 350225674)
14. Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Gilks CF, Brindle RJ, Otieno LS, Simani PM, Newnham RS, Bhatt SM, Lule GN, Okelo GB, Watkins WM, Waiyaki PG, et al. Lancet 1990 336 8714 545 549 10.1016/0140-6736(90)92096-Z 1975046 (Pubitemid 20278107)
15. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. Gordon MA, Banda HT, Gondwe M, Gordon SB, Boeree MJ, Walsh AL, Corkill JE, Hart CA, Gilks CF, Molyneux ME, Aids 2002 16 12 1633 1641 10.1097/00002030-200208160-00009 12172085 (Pubitemid 34921109)
16. Bacterial virulence, proinflammatory cytokines and host immunity: how to choose the appropriate Salmonella vaccine strain? Raupach B, Kaufmann SH, Microbes Infect 2001 3 14-15 1261 1269 11755414 (Pubitemid 34033761)
17. Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Dunstan SJ, Simmons CP, Strugnell RA, Infect Immun 1998 66 2 732 740 9453634 (Pubitemid 28074220)
18. The use of live attenuated bacteria as a delivery system for heterologous antigens. Garmory HS, Leary SE, Griffin KF, Williamson ED, Brown KA, Titball RW, J Drug Target 2003 11 8-10 471 479 15203915 (Pubitemid 38519156)
19. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Hohmann EL, Oletta CA, Miller SI, Vaccine 1996 14 1 19 24 10.1016/0264-410X(95)00173-X 8821644 (Pubitemid 26046542)
20. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Tacket CO, Kelly SM, Schodel F, Losonsky G, Nataro JP, Edelman R, Levine MM, Curtiss R 3rd, Infect Immun 1997 65 8 3381 3385 9234801 (Pubitemid 27342425)
21. Live Salmonella as vaccines and carriers of foreign antigenic determinants. Chatfield SN, Strugnell RA, Dougan G, Vaccine 1989 7 6 495 498 10.1016/0264-410X(89)90271-5 2481908 (Pubitemid 20064259)
22. Salmonella enterica serovar typhimurium strains with regulated delayed attenuation in vivo. Curtiss R 3rd, Wanda SY, Gunn BM, Zhang X, Tinge SA, Ananthnarayan V, Mo H, Wang S, Kong W, Infect Immun 2009 77 3 1071 1082 10.1128/IAI.00693-08 19103774
23. Salmonella DNA adenine methylase mutants confer cross-protective immunity. Heithoff DM, Enioutina EY, Daynes RA, Sinsheimer RL, Low DA, Mahan MJ, Infect Immun 2001 69 11 6725 6730 10.1128/IAI.69.11.6725-6730.2001 11598044 (Pubitemid 32995430)
24. Oral immunization with ATP-dependent protease-deficient mutants protects mice against subsequent oral challenge with virulent Salmonella enterica serovar typhimurium. Matsui H, Suzuki M, Isshiki Y, Kodama C, Eguchi M, Kikuchi Y, Motokawa K, Takaya A, Tomoyasu T, Yamamoto T, Infect Immun 2003 71 1 30 39 10.1128/IAI.71.1.30-39.2003 12496146 (Pubitemid 36026001)
25. Effect of different purine auxotrophic mutations on mouse-virulence of a Vi-positive strain of Salmonella dublin and of two strains of Salmonella typhimurium. McFarland WC, Stocker BA, Microb Pathog 1987 3 2 129 141 10.1016/0882-4010(87)90071-4 2849016
26. The PhoP virulence regulon and live oral Salmonella vaccines. Miller SI, Loomis WP, Alpuche-Aranda C, Behlau I, Hohmann E, Vaccine 1993 11 2 122 125 10.1016/0264-410X(93)90006-J 8438611 (Pubitemid 23031496)
27. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Angelakopoulos H, Hohmann EL, Infect Immun 2000 68 4 2135 2141 10.1128/IAI.68.4.2135-2141.2000 10722611 (Pubitemid 30164846)
28. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA, Ghaem-Maghami M, Sexton A, Khan M, Brennan FR, et al. Infect Immun 2002 70 7 3457 3467 10.1128/IAI.70.7.3457- 3467.2002 12065485 (Pubitemid 34665982)
29. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, et al. J Clin Oncol 2002 20 1 142 152 10.1200/JCO.20.1.142 11773163 (Pubitemid 34032605)
30. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. Hone DM, Tacket CO, Harris AM, Kay B, Losonsky G, Levine MM, J Clin Invest 1992 90 2 412 420 10.1172/JCI115876 1644914
31. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Dilts DA, Riesenfeld-Orn I, Fulginiti JP, Ekwall E, Granert C, Nonenmacher J, Brey RN, Cryz SJ, Karlsson K, Bergman K, et al. Vaccine 2000 18 15 1473 1484 10.1016/S0264-410X(99)00424-7 10618545 (Pubitemid 30017828)
32. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Kotton CN, Lankowski AJ, Scott N, Sisul D, Chen LM, Raschke K, Borders G, Boaz M, Spentzou A, Galan JE, et al. Vaccine 2006 24 37-39 6216 6224 16824652 (Pubitemid 44247245)
33. Salmonella-based vaccines for infectious diseases. Kwon YM, Cox MM, Calhoun LN, Expert Rev Vaccines 2007 6 2 147 152 10.1586/14760584.6.2.147 17408365 (Pubitemid 46607451)
34. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea. Endt K, Stecher B, Chaffron S, Slack E, Tchitchek N, Benecke A, Van Maele L, Sirard JC, Mueller AJ, Heikenwalder M, et al. PLoS Pathog 2010 6 9 1001097 10.1371/journal.ppat.1001097 20844578
35. Simultaneous identification of bacterial virulence genes by negative selection. Hensel M, Shea JE, Gleeson C, Jones MD, Dalton E, Holden DW, Science 1995 269 5222 400 403 10.1126/science.7618105 7618105
36. Influence of the Salmonella typhimurium pathogenicity island 2 type III secretion system on bacterial growth in the mouse. Shea JE, Beuzon CR, Gleeson C, Mundy R, Holden DW, Infect Immun 1999 67 1 213 219 9864218 (Pubitemid 29021651)
37. Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice. Periaswamy B, Maier L, Vishwakarma V, Slack E, Kremer M, Andrews-Polymenis HL, McClelland M, Grant AJ, Suar M, Hardt WD, PLoS One 2012 7 9 45433 10.1371/journal.pone.0045433 23029007
38. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Fang FC, Nat Rev Microbiol 2004 2 10 820 832 10.1038/nrmicro1004 15378046 (Pubitemid 39317463)
39. mig-14 is a horizontally acquired, host-induced gene required for salmonella enterica lethal infection in the murine model of typhoid fever. Valdivia RH, Cirillo DM, Lee AK, Bouley DM, Falkow S, Infect Immun 2000 68 12 7126 7131 10.1128/IAI.68.12.7126-7131.2000 11083839 (Pubitemid 32463428)
40. Mig-14 is an inner membrane-associated protein that promotes Salmonella typhimurium resistance to CRAMP, survival within activated macrophages and persistent infection. Brodsky IE, Ghori N, Falkow S, Monack D, Mol Microbiol 2005 55 3 954 972 15661016 (Pubitemid 40203706)
41. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Hoiseth SK, Stocker BA, Nature 1981 291 5812 238 239 10.1038/291238a0 7015147 (Pubitemid 11081517)
42. A novel phage element of Salmonella enterica serovar Enteritidis P125109 contributes to accelerated type III secretion system 2-dependent early inflammation kinetics in a mouse colitis model. Vishwakarma V, Periaswamy B, Bhusan Pati N, Slack E, Hardt WD, Suar M, Infect Immun 2012 80 9 3236 3246 10.1128/IAI.00180-12 22753379
43. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Datsenko KA, Wanner BL, Proc Natl Acad Sci USA 2000 97 12 6640 6645 10.1073/pnas.120163297 10829079 (Pubitemid 30412767)
44. The Salmonella pathogenicity island (SPI)-2 and SPI-1 type III secretion systems allow Salmonella serovar typhimurium to trigger colitis via MyD88-dependent and MyD88-independent mechanisms. Hapfelmeier S, Stecher B, Barthel M, Kremer M, Muller AJ, Heikenwalder M, Stallmach T, Hensel M, Pfeffer K, Akira S, et al. J Immunol 2005 174 3 1675 1685 15661931
45. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Barthel M, Hapfelmeier S, Quintanilla-Martinez L, Kremer M, Rohde M, Hogardt M, Pfeffer K, Russmann H, Hardt WD, Infect Immun 2003 71 5 2839 2858 10.1128/IAI.71.5.2839-2858.2003 12704158 (Pubitemid 36519898)
46. Virulence of broad- and narrow-host-range Salmonella enterica serovars in the streptomycin-pretreated mouse model. Suar M, Jantsch J, Hapfelmeier S, Kremer M, Stallmach T, Barrow PA, Hardt WD, Infect Immun 2006 74 1 632 644 10.1128/IAI.74.1.632-644.2006 16369020 (Pubitemid 43023119)
47. Accelerated type III secretion system 2-dependent enteropathogenesis by a Salmonella enterica serovar enteritidis PT4/6 strain. Suar M, Periaswamy B, Songhet P, Misselwitz B, Muller A, Kappeli R, Kremer M, Heikenwalder M, Hardt WD, Infect Immun 2009 77 9 3569 3577 10.1128/IAI.00511-09 19528213
48. Peroral ciprofloxacin therapy impairs the generation of a protective immune response in a mouse model for Salmonella enterica serovar Typhimurium diarrhea, while parenteral ceftriaxone therapy does not. Endt K, Maier L, Kappeli R, Barthel M, Misselwitz B, Kremer M, Hardt WD, Antimicrob Agents Chemother 2012 56 5 2295 2304 10.1128/AAC.05819-11 22354292
49. CD40 ligand deficiency presenting as unresponsive neutropenia. Andrews FJ, Katz F, Jones A, Smith S, Finn A, Arch Dis Child 1996 74 5 458 459 10.1136/adc.74.5.458 8669967 (Pubitemid 26171560)
50. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. Padigel UM, Alexander J, Farrell JP, J Immunol 2003 171 7 3705 3710 14500669 (Pubitemid 37254575)
51. Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. Levine MM, Black RE, Lanata C, J Infect Dis 1982 146 6 724 726 10.1093/infdis/146.6.724 7142746 (Pubitemid 13211867)
52. Waterborne typhoid fever in Dade County, Florida. Clinical and therapeutic evaluation of 105 bacteremic patients. Hoffman TA, Ruiz CJ, Counts GW, Sachs JM, Nitzkin JL, Am J Med 1975 59 4 481 487 10.1016/0002-9343(75)90255- 7 1166856
53. mig-14 is a Salmonella gene that plays a role in bacterial resistance to antimicrobial peptides. Brodsky IE, Ernst RK, Miller SI, Falkow S, J Bacteriol 2002 184 12 3203 3213 10.1128/JB.184.12.3203-3213.2002 12029036 (Pubitemid 34568929)